|
Myrophine
|
|
| Systematic (IUPAC) name | |
| 7,8-didehydro-4,5α-epoxy-17-methyl-3-(phenylmethoxy)-morphinan-6-ol tetradecanoate | |
| Identifiers | |
| CAS number | |
| ATC code | none |
| PubChem | |
| Chemical data | |
| Formula | C38H51NO4 |
| Mol. mass | 585.82 g/mol |
| Synonyms | Myristylbenzylmorphine |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Myrophine (Myristylbenzylmorphine) is an opiate analogue that was developed in 1952. It is a derivative of morphine.
Myrophine is substituted with a 3-benzyl group and a 6-myristyl chain. It is metabolised to form benzylmorphine and then further to morphine, and so is a long-acting prodrug for morphine, but with a slow onset of effects. It is a Schedule I drug in the USA and is controlled under international drug conventions. Myrophine is almost invariably used as the hydrochloride (free base conversion ratio 0.94) and has a DEA Administrative Controlled Substance Control Number of 9308.
References
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)




